

LANKA 202.

# WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health, Nutrition & Indigenous Medicine 231, de Saram Place, Colombo 01000, Sri Lanka Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk Web: http://www.epid.gov.lk

### Vol. 49 No. 38

### 17<sup>th</sup>- 23<sup>rd</sup> Sep 2022

#### The link between COVID-19 infection and Cardio-vascular disease Part I

This is a first part of a article that The link between COVID-19 infection and Cardiovascular disease

#### Introduction –

#### Coronavirus disease

Coronavirus disease (COVID-19) is a viral infection caused by the SARS-CoV-2 virus. It is an infectious disease that evolved into a global pandemic<sup>1</sup>. It was the 7<sup>th</sup> known human coronavirus to cause disease in human<sup>2</sup>. The virus is spread by respiratory droplets. The virus can also spread by direct contact with symptomatic or asymptomatic patients<sup>3</sup>. Respiratory symptoms of mild to moderate severity are observed in most of the patients. They usually require no special treatment. However, some persons will show severe symptoms requiring medical attention. The vulnerable groups are older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer. However, anyone at any age can get the COVID-19 infection and develop the serious disease or die<sup>1</sup>.

#### Cardiovascular diseases

Cardiovascular diseases are diseases affecting the heart and blood vessels. Among them, coronary heart disease and cerebrovascular disease (stroke) are encountered usually. Others include peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis (DVT) and pulmonary embolism (PE). Acute coronary heart disease and acute cerebrovascular disease (strokes) are mainly due to a blockage that averts blood from flowing to the heart or brain respectively. The obstruction is commonly due to the deposits of fat that accumulate on the

surface of the inner walls of the vessels providing blood to the heart or brain. Strokes can occur due to bleeding from a blood vessel in the brain or from a blood clot. Considering all global deaths in 2019, 32 % of deaths were due to cardiovascular diseases. Thus, it became the leading cause of death globally. Of these deaths, the majority (85%) were due to heart attack and stroke. More than 75 % of the deaths due to cardiovascular disease take place in low and middle-income countries. However, most cardiovascular diseases can be averted by addressing behavioural risk factors for cardiovascular diseases such as tobacco use, obesity, unhealthy diet, physical inactivity and harmful use of alcohol, 4


# Mechanism of action (SARS-COV-2 virus)

SARS-Cov-2 is a single-stranded enveloped RNA virus. Angiotensin-converting enzyme 2 (ACE 2) is the main receptor for the SARS-Cov-2 virus. A spike glycoprotein on the envelope of the SARS-Cov-2 virus binds to the ACE 2 receptor on the host cells allowing the virus to enter the host cells. ACE 2 receptors are present in many organs in the human body in varying degrees. In the respiratory system, it is present mainly in the lung, especially on type II alveolar epithelial cells. It is weakly expressed in the oral and nasal mucosa and nasopharynx. Thus, the lungs have become the primary target for the SARS-Cov-2 virus. Also, ACE2 is highly expressed in the myocardial cells. It counteracts the effects of angiotensin II in conditions with excessive activation of the reninangiotensin system (e.g. hypertension, atherosclerosis and congestive heart failure)<sup>3</sup> Furthermore, ACE 2 is also expressed in proximal tubule cells of the kidney, urothelial cells of the bladder and enterocytes of the small intestine mainly in the ileum.

Contents	Page
1. The link between COVID-19 infection and Cardio-vascular	isease Part I 1
2. Summary of selected notifiable diseases reported $(10^{\text{th}} - 16^{\text{th}})$	September 2022 ) 3
3. Surveillance of vaccine preventable diseases & AFP ( $10^{\text{th}} - 1$	th September 2022) 4

## *WER Sri Lanka* - Vol. 49 No. 38

Thus, it provides a mechanism for the multi-organ dysfunction that can occur with SARS-CoV-2 infection. Through blood circulation, a cell-free and macrophage phagocytosis-associated virus may spread from the lungs to other organs with high ACE2 expression <sup>3</sup>.



#### Figure 1- Schematic model of COVID-19 and CVD<sup>7</sup>

#### Cardio-vascular effects in COVID-19

There is growing evidence showing the association of COVID-19 with increased morbidity and mortality from cardiovascular disease (CVD).

The incidence of cardiovascular manifestations is high with COVID-19 infection. It is mainly due to the systemic inflammatory response and immune system disorders that take place during disease progression. One proposed mechanism of cardiac involvement is direct myocardial injury mediated via ACE2. The other proposed mechanisms are cytokine involvement and respiratory dysfunction caused by COVID-19, which is detrimental to myocardial cells. However, the exact mechanism of cardiac involvement in COVID-19 remains unclear

#### Myocardial injury (MI)

Myocardial injury is diagnosed with elevated levels of cardiac biomarkers or abnormality in electrocardiography (ECG) and echocardiography. According to a clinical case series, the incidence of MI in patients who were diagnosed with COVID-19 ranges from 7.2% to 19.2%. Thus, the incidence was relatively high among COVID-19 patients and it was positively related to mortality. Based on the biomarkers, MI in COVID-19 patients can be ascribed to two patterns. One of the patterns reflects cytokine storm and the other presents with predominantly cardiac symptoms indicating viral myocarditis or stress cardiomyopathy

Compiled by: Dr Morina Fernando Epidemiology Unit

Table 1 : Water Quality SurveillanceNumber of microbiological water samples2022										
District	MOH areas	No: Expected *	No: Received							
Colombo	15	90	NR							
Gampaha	15	90	NR							
Kalutara	12	72	NR							
Kalutara NIHS	2	12	NR							
Kandy	23	138	NR							
Matale	13	78	10							
Nuwara Eliya	13	78	NR							
Galle	20	120	NR							
Matara	17	102	NR							
Hambantota	12	72	NR							
Jaffna	12	72	167							
Kilinochchi	4	24	NR							
Manner	5	30	0							
Vavuniya	4	24	43							
Mullatvu	5	30	0							
Batticaloa	14	84	NR							
Ampara	7	42	35							
Trincomalee	11	66	NR							
Kurunegala	29	174	NR							
Puttalam	13	78	NR							
Anuradhapura	19	114	NR							
Polonnaruwa	7	42	0							
Badulla	16	96	NR							
Moneragala	11	66	NR							
Rathnapura	18	108	NR							
Kegalle	11	66	0							
Kalmunai	13	78	0							

\* No of samples expected (6 / MOH area / Month) NR = Return not received

## WER Sri Lanka - Vol. 49 No . 38

## 17<sup>th</sup>- 23<sup>rd</sup> Sep 2022

ipl	le 1:	: Se	elect	ed	noti	fiab	le d	ise	ase	s re	port	ed b	ov M	edi	cal (	Offic	cers	of	Hea	lth	1	0 <sup>th_</sup>	16 <sup>th</sup>	Se	p 20	22 (	37 <sup>th</sup>	We	ek
	č*	95	85	52	97	66	93	66	66	66	93	96	77	95	91	97	93	84	96	89	88	96	66	97	92	97	98	94	
WKGD	*	15	9	m	13	18	27	13	16	30	64	27	19		22	39	11	17	10	15	10	15	17	11	13	10	30	18	
lania-		2	29	2	24	258	0	0	395	209	0	2	0	4		1	12	1	358	4	291	374	17	112	168	18	0	2282	
Leishmania-	AB	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	B	10	31	19	7	1	9	17	15	9	11	2	15	0		30	20	9	32	23	38	m	11	37	48	41	32	462	
Meningitis	Ā	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		32	41	58	57	33	33	60	24	37	88	4	9	27	9	25	41	33	72	13	52	15	4	51	63	81	48	1044	
Chickenpox	AB	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	
_	B /	2	4	m	0	H	0	0	0	0	4	0	0	0	0	H	0	0	2	0		0	0	0	0	0	0	18	
Human	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Viral Hepa-	в	ъ	10	4	6	ъ	9	ы	9	ч	9	0	2	0	0	H	H	4		н	2	m	117	46	21	8	H	265	
Viral	A	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	H	
<u>n</u>	в	0	0	4	30	ъ	12	27	35	12	415	10	m	н	ъ	0	H	ω	25	7	21	0	41	24	21	18	H	721	
Iyphus	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
Leptospirosis		146	147	295	124	79	62	328	191	195	20	11	23	18	25	36	84	24	124	22	135	97	188	235	733	388	21	3751	
eptosp	8		<del></del>	9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	ø	
	•	9	12	9	11	0	2	0	2	0	30	24	0	0	9	20	17	2	4	0	ъ	-	13	m	27	8	9	208	
2000 7	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Enteric Fever Food Poi	A			7	m	0	m	0	0	0	- 28	m	0	5	2	0	0	н Н	0	0		0		4	m	-		87	
interic	8	0	0		0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	
haliti E	B	m			0	0	0		0	2	2	0	0		0	7		0	2	0	2	-	2	1	9	8		42	
Encephaliti	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
	В	4	S	22	19	8	19	6	29	12	20	7	2	m	ъ	53	10	23	18	m	6	9	19	9	39	12	29	421	
nyse	A	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Dengue Fever Dysentery	8	9785	6067	3117	4011	862	186	2996	1337	1367	2542	102	177	70	54	1020	134	966	2203	1686	350	121	845	390	2321	2316	890	45945	
Deng	A	21	б	23	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	23	
KDHS		Colombo	Gampaha	Kalutara	ƙandy	Matale	uwaraEliya	e	Hambantota	Matara	Jaffna	ilinochchi	Mannar	/avuniya	Mullaitivu	Batticaloa	Ampara	rincomalee	Kurunegala	Puttalam	nuradhapur	Polonnaruwa	Badulla	Monaragala	Ratnapura	<b>Kegalle</b>	(almune	SRILANKA	

Page 3

## WER Sri Lanka - Vol. 48 No. 38

## Table 2: Vaccine-Preventable Diseases & AFP

## 10<sup>th-16th</sup> Sep 2022 (37<sup>th</sup> Week)

17th-23rd Sep 2022

Disease		N	lo. of	Case	es b	y Pro	ovinc	e	Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date	
	w	С	S	N	Е	NW	NC	U	Sab	week in 2022	week in 2021	2022	2021	in 2022 & 2021
AFP*	00	00	00	00	00	01	00	01	00	02	03	57	46	23.9 %
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Mumps	00	00	00	00	00	00	00	00	00	00	01	63	58	8.6 %
Measles	00	01	00	00	00	00	00	00	00	01	00	17	11	54.5 %
Rubella	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Tetanus	00	00	00	00	00	00	00	00	00	00	00	05	02	150 %
Neonatal Tetanus	00	00	00	00	00	00	00	00	00	00	00	00	00	0 %
Japanese En- cephalitis	00	00	00	00	00	00	00	00	00	00	00	01	03	- 66.6 %
Whooping Cough	00	00	00	00	00	00	00	00	00	00	00	01	00	0 %
Tuberculosis	00	06	03	05	03	00	00	14	23	54	196	4790	3625	32.1 %

#### Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna, KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam, AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS, Special Surveillance: AFP\* (Acute Flaccid Paralysis), Japanese Encephalitis

**CRS**\*\* =Congenital Rubella Syndrome

NA = Not Available

Influenza Surveillance in Sentinel Hospitals - ILI & SARI													
Month	Human		Animal										
	No Total	No Positive	Infl A	Infl B	Pooled samples	Serum Samples	Positives						
September													
Source: Medical Research Institute & Veterinary Research Institute													

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

## **ON STATE SERVICE**

Dr. Samitha Ginige Actg. CHIEF EPIDEMIOLOGIST EPIDEMIOLOGY UNIT 231, DE SARAM PLACE COLOMBO 10

Data Sources: